CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore the MTD of CD5CART treatment of relapsed and refractory subjects with CD5 hematological malignancies. At the same time, the effectiveness and pharmacokinetic characteristics of CD5CART treatment of relapsed and refractory CD5 hematological tumors in subjects were explored

NCT Number	NCT07234110
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Beijing Gaobo Boren Hospital
Conditions	Relapsed and Refractory CD5 Hematological Tumors
Enrollment	18 participants
Start Date	2025-09-03
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-30